Drug Profile
LY 3192767
Alternative Names: LY3192767Latest Information Update: 28 Apr 2020
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antihyperglycaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 28 Apr 2020 No recent reports of development identified for phase-I development in Diabetes-mellitus(In volunteers) in Germany (SC, Injection)
- 26 Jul 2018 Eli Lilly terminates a phase I trial due to immunogenicity rate, injection site reactions, and business reasons in Diabetes mellitus (In volunteers) in Germany (SC) (NCT03025009)
- 11 Apr 2018 Eli Lilly completes a phase I trial in Diabetes mellitus (In volunteers) in Germany (SC) (NCT03025009)